Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026.

The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre‑funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of their option to purchase additional shares of stock in the offering. All shares and pre-funded warrants were sold by Zura.

Gross proceeds from the offering were approximately $144 million, before deducting underwriting discounts and commissions and other offering expenses payable by Zura.

Leerink Partners, Piper Sandler and Cantor acted as joint bookrunning managers for the offering. Wedbush PacGrow acted as lead manager.

The Class A ordinary shares and pre‑funded warrants were offered by Zura pursuant to a shelf registration statement on Form S‑3, as amended (Registration No. 333‑281905), that was filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on September 17, 2024. The offering was made by means of a prospectus supplement and accompanying prospectus filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained by visiting the SEC’s website at www.sec.gov.

ABOUT ZURA

Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.

Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260227534816/en/